Education
About Us
Working with TipRanks
Follow Us
Affimed Therapeutics (GB:0HL9)
:0HL9
0HL9 Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.91 - $8.90
Previous CloseN/A
Volume52.99K
Average Volume (3M)11.30K
Market Cap
$14.08M
Enterprise Value$41.58M
Total Cash (Recent Filing)€94.83M
Total Debt (Recent Filing)€4.77M
Price to Earnings (P/E)―
Beta1.82
Next Earnings
Mar 27, 2025EPS Estimate
-0.88Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.64
Shares Outstanding15,227,463
10 Day Avg. Volume6,609
30 Day Avg. Volume11,300
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)1.76
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$7.67Price Target Upside674.75% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
---
Affimed News
PremiumCompany Announcements
Affimed’s Promising Clinical Update on NSCLC Treatment
---
Bulls Say, Bears Say
Bulls Say
Partnership And FinancingAffimed’s three active molecules should be of interest to pharma, and a partnership with non-dilutive financing would provide significant support for the stock.
Bears Say
Delay And UncertaintyThere is a 1-1.5 year delay and uncertainty in source of funding for the higher dose strategy.
Funding And Financial ConcernsThe initiation of the PTCL cohort in LuminICE-203 is contingent upon securing additional capital.
---
Options Prices
Currently, No data available
---
Ownership Overview
―
Insiders
1.59% Mutual Funds
9.37% Other Institutional Investors
89.04% Public Companies and Individual Investors
0HL9 FAQ
What was Affimed Therapeutics’s price range in the past 12 months?
Affimed Therapeutics lowest share price was $0.91 and its highest was $8.89 in the past 12 months.
What is Affimed Therapeutics’s market cap?
Affimed Therapeutics’s market cap is $14.08M.
When is Affimed Therapeutics’s upcoming earnings report date?
Affimed Therapeutics’s upcoming earnings report date is Mar 27, 2025 which is in 15 days.
How were Affimed Therapeutics’s earnings last quarter?
Affimed Therapeutics released its earnings results on Nov 14, 2024. The company reported -$0.979 earnings per share for the quarter, missing the consensus estimate of -$0.962 by -$0.018.
Is Affimed Therapeutics overvalued?
According to Wall Street analysts Affimed Therapeutics’s price is currently Undervalued.
Does Affimed Therapeutics pay dividends?
Affimed Therapeutics does not currently pay dividends.
What is Affimed Therapeutics’s EPS estimate?
Affimed Therapeutics’s EPS estimate is -0.88.
How many shares outstanding does Affimed Therapeutics have?
Affimed Therapeutics has 15,227,463 shares outstanding.
What happened to Affimed Therapeutics’s price movement after its last earnings report?
Affimed Therapeutics reported an EPS of -$0.979 in its last earnings report, missing expectations of -$0.962. Following the earnings report the stock price went up 1.964%.
Which hedge fund is a major shareholder of Affimed Therapeutics?
Currently, no hedge funds are holding shares in GB:0HL9
---
Company Description
Affimed Therapeutics
Affimed NV engages in discovering and developing of targeted cancer immunotherapies. Its pipelines include Innate Cell Engagers and T Cell Engagers. The company was founded in 2000 and is headquartered in Heidelberg, Germany.
---
0HL9 Company Deck
---
0HL9 Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call highlighted significant progress in clinical trials, particularly with AFM24 and AFM28, and a strategic focus on partnerships and financial health. However, there were notable challenges, including a decline in revenue and reduced cash reserves. Despite these challenges, the company's efforts to improve its financial position and strategic focus are promising.Read More>---
0HL9 Stock 12 Month Forecast
Average Price Target
$7.67
▲(674.75% Upside)
Technical Analysis
Best Analysts Covering 0HL9
1 Year
1 Year Success Rate
1/20 ratings generated profit
1 Year Average Return
-51.87%
reiterated a buy rating 3 months ago
Copying Daina Graybosch's trades and holding each position for 1 Year would result in 5.00% of your transactions generating a profit, with an average return of -51.87% per trade.
---